BICO (HUREL CORP.)

Company Snapshot

Founded: 2016
Entity Type: Public
Employees: 711
Region: U.S.
Revenue: $184.1 Millions
Revenue Year: 2024
Headquarter: Goteborg, Sweden
Key Geographics: North America, Europe, Asia-Pacific, Other Countries

Company Overview

BICO specializes in advancing and commercializing bioprinting technologies, facilitating the printing of three-dimensional (3D) human organs and tissues for research purposes. Their product range includes bioprinters, drug screening tools, dispensing solutions, automated non-contact plate washers and liquid dispensers. Additionally, they offer pheromone, a platform for sorting and dispensing single large particles. BICO serves a diverse clientele, including research institutions and pharmaceutical, biopharmaceutical, automotive, and cosmetic companies.
Cellink and MatTek are the subsidiaries of BICO.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

BICO (HUREL CORP.) In Reports

3D Cell Cultures: Technologies and Global Markets

BCC Research Market Analyst says global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028 at a CAGR of 26.5% from 2023 through 2028.

Organ-on-a-Chip: Global Markets

BCC Research Market Report for organ-on-a-chip market should reach $183.4 million by 2026 from $32.0 million in 2021 at a compound annual growth rate (CAGR) of 41.8%

In Vitro Toxicity Testing: Technologies and Global Markets

BCC Research Market Report for In Vitro Toxicity Testing market. global In Vitro Toxicity Testing market trends, with CAGRs through 2026.

Applications/End User Industries

  • Lab Automation
  • Life Science Solutions
  • Bioprinting